Xinglei Chai

Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers

Xinglei Chai, Tara M. Friebel, Christian F. Singer et al. · Breast Cancer Research and Treatment · 2014 · 65 citations · Full text

Medicine, Genetics, Surgery +16

Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan

Shiho Wakase, Takanori Teshima, Jie Zhang et al. · Transplantation and Cellular Therapy · 2020 · 27 citations · Full text

Medicine, Hematology, Oncology +17

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

Keith W. Pratz, Xinglei Chai, Jipan Xie et al. · PharmacoEconomics · 2022 · 14 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15

Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital’s perspective

Hongbo Yang, Yanni Hao, Xinglei Chai et al. · Journal of Medical Economics · 2020 · 12 citations · Full text

Pharmacy, Hematology, Pharmacoeconomics +17

Breast and ovarian cancer penetrance of <i>BRCA1/2</i> mutations among Hong Kong women

Lingjiao Zhang, Vivian Y. Shin, Xinglei Chai et al. · Oncotarget · 2018 · 11 citations · Full text

Life Sciences, Genetics, Oncology +15